RPL7L1

Across TCGA pan-cancer cohorts, RPL7L1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RPL7L1 data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher RPL7L1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RPL7L1 expression acts as an unfavorable survival marker.

BRCA, STAD, and UCEC are the cancer types where RPL7L1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.088	0.924	<.001	24	view →
STAD	DFS	Median	All	0.210	0.709	.010	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RPL7L1–BRCA (OS)

Open the BRCA breakdown →